When applying oral H3R agonist treatment around peak disease in the EAE animal model for MS, where microglial cells were shown to promote inflammation (57, 58), we observed significantly attenuated clinical scores and reduced inflammatory microglial cells in the spinal cord (Supplemental Figure 6), as seen in CIA mice. This evidence concerns the gene HRH3 and myeloid sarcoma.